levofloxacin has been researched along with gemifloxacin in 58 studies
Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (gemifloxacin) | Trials (gemifloxacin) | Recent Studies (post-2010) (gemifloxacin) |
---|---|---|---|---|---|
4,346 | 581 | 2,209 | 320 | 46 | 80 |
Protein | Taxonomy | levofloxacin (IC50) | gemifloxacin (IC50) |
---|---|---|---|
DNA gyrase subunit B | Staphylococcus aureus | 5.6 | |
DNA gyrase subunit A | Escherichia coli K-12 | 0.5 | |
DNA gyrase subunit B | Escherichia coli K-12 | 0.5 | |
DNA topoisomerase 4 subunit A | Staphylococcus aureus | 0.3 | |
DNA gyrase subunit A | Staphylococcus aureus | 5.6 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 36 (62.07) | 29.6817 |
2010's | 21 (36.21) | 24.3611 |
2020's | 1 (1.72) | 2.80 |
Authors | Studies |
---|---|
Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
Klugman, KP; Levin, BR; McGee, L; Rozen, DE | 1 |
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B | 1 |
Morgan-Linnell, SK; Zechiedrich, L | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
Chai, Y; Guo, HY; Liu, ML; Wan, ZL; Wang, B | 1 |
Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E | 1 |
Appelbaum, PC; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
Al-Trawneh, SA; Alfieri, RR; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Kamal, MR; Petronini, PG; Vicini, P; Zahra, JA; Zani, F | 1 |
Chai, Y; Feng, LS; Guo, HY; Guo, Q; Han, LY; Liu, ML; Lv, K; Zhang, YB | 1 |
Cao, J; Feng, L; Guo, H; Li, G; Liu, M; Lv, K; You, X; Zhang, Y | 1 |
Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
Al-Taweel, SA; Al-Trawneh, SA; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Vicini, P; Zahra, JA; Zani, F | 1 |
Chai, Y; Guo, HY; Li, SJ; Liu, ML; Wang, B; Wang, JX; Zhang, YB | 1 |
Chai, Y; Guo, H; Liu, M; Sun, L; Wang, J; Yi, H; You, X | 1 |
Cao, J; Feng, L; Guo, H; Li, S; Liu, M; Lv, K; Wang, S; You, X; Zhao, J | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Cao, J; Guo, H; Liu, M; Lv, K; Sun, Y; Wang, J; Wei, Z; Wu, J | 1 |
Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
Kanayama, A; Kobayashi, I; Mochida, O; Naito, S; Saika, T; Tanaka, M; Tunoe, H | 1 |
Ferraro, MJ; Jorgensen, JH; Swenson, JM; Tenover, FC; Weigel, LM; Whitney, CG | 1 |
Bouchillon, SK; Butler, DL; Hoban, DJ; Johnson, JL; Karlowsky, JA; Miller, LA; Poupard, JA | 1 |
Doyle, E; Edelstein, MA; Edelstein, PH; Shinzato, T | 1 |
Rossi, C; Sternon, J | 1 |
Bouchillon, SK; Butler, DL; Hoban, DJ; Johnson, JL; Miller, LA; Poupard, JA; Zhanel, GG | 1 |
Evans, ME | 1 |
Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
Bowker, KE; MacGowan, AP | 1 |
Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
Aguilar, L; García-Calvo, G; García-Olmos, M; Giménez, MJ; Parra, A; Ponte, C; Soriano, F | 1 |
Aguilar, L; Garcia-Mendez, E; Jiménez De Anta, MT; Marco, F; Mensa, J; Ruiz, J; Sierra, JM; Vila, J | 1 |
Leggett, J; Saravolatz, LD | 1 |
Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA | 1 |
Martinez, FJ | 1 |
Fogarty, C; Fulambarker, A; Sethi, S | 1 |
Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D | 1 |
Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J | 1 |
Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C | 1 |
Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
Bast, DJ; de Azavedo, JC; Dresser, L; Duncan, CL; Low, DE; Mandell, LA; Walker, SE | 1 |
Hsueh, PR; Lee, PI; Yang, JC | 1 |
Schafer, KR; Wispelwey, B | 1 |
Chen, H; Jiang, H; Liu, T; Song, Z; Wu, X; Xu, Y; Yang, L; Yue, W | 1 |
Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ | 1 |
Attaran, B; Eskini, N; Esmaeili, M; Mohammadi, M; Sadeghi, M; Salehi, N; Sharifirad, A | 1 |
Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
4 review(s) available for levofloxacin and gemifloxacin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quinolone antibiotics.
Topics: | 2019 |
[Third and fourth generation fluoroquinolones].
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug Monitoring; Drug Resistance; Fluoroquinolones; Gemifloxacin; Humans; Intestinal Absorption; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Patient Selection; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome | 2001 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae | 2010 |
1 trial(s) available for levofloxacin and gemifloxacin
Article | Year |
---|---|
A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Male; Middle Aged; Naphthyridines; Ofloxacin; Treatment Outcome | 2004 |
53 other study(ies) available for levofloxacin and gemifloxacin
Article | Year |
---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial | 2007 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan | 2008 |
Synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-amino-3-methylpiperidin-1-yl)fluoroquinolone derivatives.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Cell Survival; Chlorocebus aethiops; Fluoroquinolones; Microbial Sensitivity Tests; Structure-Activity Relationship; Vero Cells | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae | 2010 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors | 2010 |
Synthesis and in vitro antibacterial activity of fluoroquinolone derivatives containing 3-(N'-alkoxycarbamimidoyl)-4-(alkoxyimino) pyrrolidines.
Topics: Anti-Bacterial Agents; Crystallography, X-Ray; Fluoroquinolones; Magnetic Resonance Spectroscopy; Pyrrolidines; Spectrometry, Mass, Electrospray Ionization | 2010 |
Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae | 2011 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Thienopyridines; Topoisomerase II Inhibitors | 2011 |
Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-4-amino-4-methylpiperidin-1-yl) fluoroquinolone derivatives.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Cell Line; Cell Survival; Crystallography, X-Ray; Dogs; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fluoroquinolones; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcus; Stereoisomerism; Structure-Activity Relationship | 2011 |
Design, synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-aminomethylpiperidin-1-yl)fluoroquinolone derivatives.
Topics: Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Imino Pyranoses; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa | 2011 |
Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety.
Topics: Anti-Bacterial Agents; Bacteria; Chemistry Techniques, Synthetic; Fluoroquinolones; Gemifloxacin; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Naphthyridines; Oximes | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Synthesis and in vitro antibacterial activity of quinolone/naphthyridone derivatives containing 3-alkoxyimino-4-(methyl)aminopiperidine scaffolds.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Piperidines; Quinolones; Structure-Activity Relationship | 2013 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Gonorrhea; Humans; Levofloxacin; Naphthyridines; Neisseria gonorrhoeae; Norfloxacin; Ofloxacin | 2000 |
Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Streptococcus pneumoniae | 2000 |
A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.
Topics: Adolescent; Adult; Anti-Infective Agents; Drug Resistance, Microbial; Europe; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Naphthyridines; North America; Ofloxacin; South America; Streptococcus pneumoniae | 2000 |
In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Azithromycin; Body Weight; Fluoroquinolones; Gemifloxacin; Guinea Pigs; Half-Life; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Lung; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Survival Rate | 2001 |
Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Europe; Fluoroquinolones; Gemifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin | 2001 |
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Streptococcus pneumoniae | 2001 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Topics: Anti-Infective Agents; Area Under Curve; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Half-Life; Kinetics; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Mutation; Naphthyridines; Ofloxacin; Streptococcus pneumoniae | 2003 |
Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Time Factors | 2002 |
Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Guinea Pigs; Levofloxacin; Lung; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Survival Analysis | 2003 |
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Genes, Bacterial; Gonorrhea; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Naphthyridines; Neisseria gonorrhoeae; Ofloxacin; Quinolines | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Body Temperature; Colony Count, Microbial; Disease Models, Animal; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Lung; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Mutation, Missense; Naphthyridines; Ofloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2006 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents, Local; Colony Count, Microbial; Conjunctival Diseases; Cornea; Eye; Female; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Keratitis; Levofloxacin; Male; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 2012 |
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin | 2012 |
New insights into resistance of Helicobacter pylori against third- and fourth-generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations.
Topics: Anti-Bacterial Agents; DNA Gyrase; Drug Resistance, Bacterial; Gemifloxacin; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Molecular Docking Simulation; Moxifloxacin; Mutant Proteins; Mutation; Polymerase Chain Reaction; Protein Binding; Sequence Analysis, DNA | 2019 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |